JNJ Johnson & Johnson
- Official Name: JOHNSON & JOHNSON
- Headquarters: One Johnson & Johnson Plaza, NEW BRUNSWICK, NJ, 08933 US
- CEO: Joaquin Duato
- Website: jnj.com
- Key Investor: VANGUARD GROUP INC | 9.72%
- Dedicated Investor: ROBERT WOOD JOHNSON FOUNDATION | 87.12%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-16 | 1 | Won by 4.341 TOTW | 4.824 - 0.483 | ||
| 2025-07-23 | 2 | Won by 4.924 | 5.366 - 0.442 | ||
| 2025-07-29 | 2R | Won by 3.641 | 2.329 - (1.312) | ||
| 2025-07-30 | 3 | Lost by 0.842 | (2.105) - (1.263) | ||
| 2025-08-06 | 4 | Won by 3.762 | 1.963 - (1.799) | ||
| 2025-08-07 | 1R | Won by 3.007 | 0.614 - (2.393) | ||
| 2025-08-12 | 3R | Lost by 2.389 | (0.453) - 1.936 | ||
| 2025-08-13 | 5 | Won by 0.847 | 2.590 - 1.743 | ||
| 2025-08-20 | 6 | Won by 3.910 | 2.416 - (1.494) | ||
| 2025-08-21 | 2R | Won by 1.794 | 1.364 - (0.430) | ||
| 2025-08-27 | 7 | Won by 2.957 | (1.309) - (4.266) | ||
| 2025-09-03 | 8 | Won by 5.750 | 0.712 - (5.038) | ||
| 2025-09-04 | 3R | Won by 0.099 | 0.456 - 0.357 | ||
| 2025-09-10 | 9 | Lost by 2.623 | (1.256) - 1.367 | ||
| 2025-09-11 | 4R | Lost by 0.212 | 1.572 - 1.784 | ||
| 2025-09-17 | 10 | Won by 5.920 | 0.860 - (5.060) | ||
| 2025-09-17 | 1R | Won by 0.065 | 0.400 - 0.335 | ||
| 2025-09-24 | 11 | Lost by 1.104 | (0.291) - 0.813 | ||
| 2025-10-01 | 12 | Won by 4.348 TOTW | 5.285 - 0.937 | ||
| 2025-10-01 | QF | Won by 2.833 | 0.333 - (2.500) | ||
| 2025-10-08 | 13 | Won by 3.686 | 1.933 - (1.753) | ||
| 2025-10-15 | 14 | Won by 1.620 | 0.750 - (0.870) | ||
| 2025-10-15 | SF | Won by 0.868 | 0.176 - (0.692) | ||
| 2025-10-22 | 15 | Won by 1.173 | 0.863 - (0.310) | ||
| 2025-10-22 | F | Lost by 2.165 | 0.547 - 2.712 |
Latest News

Coca-Cola and J&J Just Hit Record Highs. A 62-Year-Old Put $300,000 Into Them and Procter & Gamble in 2016. Here’s How Much the Now 72-Year-Old Gets Paid Every Single Month
A 62-year-old split $300,000 across Johnson & Johnson, Procter & Gamble and Coca-Cola on Nov. 14, 2016. Ten years of dividend raises later, he...

5 Dividend Stocks to Buy and Hold Forever
These five stocks have proven track records of dividend growth backed by attractive businesses.

3 Biotech Stocks With Revenue Up To 11%
AI related risks just jumped to the top of the Federal Reserve’s financial stability worries, with a surge in complex debt tied to AI infrastructure...

Could You Have Held Glaukos Stock Through Its Falls?
For questions about this article or underlying research, email help@trefis.com.

What Is The Market Seeing In Eli Lilly Stock?
For questions about this article or underlying research, email help@trefis.com.

4 Healthcare Dividend Stocks for Retirees. One Yields Over 4%
A fat starting yield can hide thin raises, while the slowest payers boast decades of increases. Four low-volatility healthcare blue chips force retire...

The Price Tag on Jensen Huang’s Resignation: $639 Billion and Counting
Nvidia’s market cap tumbled $639.1 billion this week, its worst weekly decline ever. The debate now is whether or not investors want to take advanta...

Did Bipolar Drug Win Just Shift JNJ's Investment Narrative?
Johnson & Johnson reported that its second pivotal Phase 3 trial of Caplyta in bipolar I mania met primary and key secondary endpoints, with clini...

Pfizer or Johnson & Johnson: The One Dividend Stock I’d Hold for the Next 20 Years
Key TakeawaysPfizer yields 6%, more than three times Johnson & Johnson’s 1. 9%, and both companies raised their 2026 guidance this fall.

What Will Decide Merck Stock Over The Next Six Months?
For questions about this article or underlying research, email help@trefis.com.

4 Dividend Kings That Kept Raising Payouts Through Recessions and High Interest Rates
Four Dividend Kings raised payouts through a financial crisis, zero rates, and the sharpest hikes in decades. Only one yields above 5%, and its thin c...

Johnson & Johnson vs. Coca-Cola: Both Have Raised Their Dividends 64 Years Straight. Which Streak Is Safer?
Key TakeawaysJohnson & Johnson (JNJ:NYSE) and Coca-Cola (KO:NYSE) yield 1. 9% and 2.

Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&J and GSK Spend Billions on Deals to Beat the Patent Cliff
Six 2026 Oncology Deals Worth Up to About USD 59 Billion Reshape a USD 279.73 Billion Market: Precedence Research Company Intelligence on Top Players,...

I Bonds Pay 5.51%. Here’s What Dividend Investors Should Know
A government-backed bond now out-yields one of the most reliable dividend payers on the market, but the headline number hides a one-year lockup, a rat...

5 Dividend Aristocrats and Kings to Consider if the Stock Market Sells Off
Market indicators are flashing red heading into October, and investors who wait too long to reposition may regret it. Five elite dividend stocks in he...

GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support going from 3 → 1 doses per treatment visitTRD pivo...

GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
Dr. Popova will lead the clinical development of GH001 as the company advances toward pivotal programs in TRD and PPDBrings more than 20 years of glob...

How Much Does a 69-Year-Old Need Invested in Dividend Stocks to Collect $3,000 a Month?
The price tag for $3,000 a month in dividends swings by more than a million dollars depending on which stocks you pick. One popular income pick looks ...

Why Is Everyone Ignoring Cooper Companies Stock's High Cash Yield?
For questions about this article or underlying research, email help@trefis.com.

While AI hogged the headlines, 1 overlooked sector beat the S&P 500 — and its top stock is up 700%+ this year
A Goldman Sachs exec now says it’s the next leg of the AI trade.

State Street Health Care SPDR (XLV) Buys $66.8 Million More Eli Lilly on Nov. 11
The fund added $396.8 million across all 60 of its positions, led by a $66.8 million increase in Eli Lilly.

ETFs Are Buying Johnson & Johnson (JNJ) on Nov. 11
ETFs bought $89.7 million of Johnson & Johnson stock on Nov. 11.

Why Did AAPL, COST, JNJ Stocks Hit 52-Week Highs Today?
Investors rotated toward defensive stocks amid AI-sector uncertainty.

Is Amgen Stock Priced Right Against Its Peers?
For questions about this article or underlying research, email help@trefis.com.

Johnson & Johnson (JNJ) Backs New Cancer Device And Leads $100 Million Depression Bet
Johnson & Johnson (NYSE: JNJ) agreed to invest in Francis Medical to help advance its Vanquish device for prostate cancer treatment. The group als...

How Did AbbVie's Immunology Franchise Fare in Q3?
ABBV's immunology sales rose 16.6% in Q3, driven by Skyrizi and Rinvoq growth, prompting higher 2026 sales forecasts despite Humira's declin...

Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund
Pfizer has an extensive clinical programme for berobenatide, acquired via its $10bn takeover of Metsera.

Johnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

J&J leads Francis Medical investment to fund prostate cancer device
With Johnson & Johnson’s support, Francis plans to take its water-vapor therapy device through the premarket approval process.

The S&P 500 Lost 5.9% in a Month, Then Won Back More Than Half in 4 Trading Days. How Much Does a 72-Year-Old Widow Need in Dividend Stocks to Collect $5,000 a Month?
A 72-year-old widow inherits her husband's portfolio and wants $5,000 every month from dividends alone. Her $1.6 million sounds like plenty, but ...

Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug
Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer’s berobenatide through 2028 in exchange for milestone-based paym...

Is There A Risk Hiding In Johnson & Johnson Stock's Earnings?
For questions about this article or underlying research, email help@trefis.com.

Johnson & Johnson vs. Procter & Gamble: 64 and 70 Straight Years of Raises. Which Dividend King Pays You More Over the Next Decade?
Key TakeawaysProcter & Gamble yields 2. 7% and Johnson & Johnson 1.

What iShares MSCI USA Momentum Factor ETF (MTUM) Sold: AMD Leads on Tuesday
The $17.32 billion fund sold $122.5 million of stock on Tuesday, cutting 123 positions and adding none.

State Street Health Care SPDR (XLV) Adds Eli Lilly and Johnson & Johnson on Nov. 10
The fund bought $132.2 million of stock, increasing all 60 of its positions and selling nothing.

JPMorgan Global Select Equity (JGLO) Adds Broadcom and AMD on Nov. 10
The fund bought $22.6 million of Broadcom and $22.0 million of AMD while selling $58.8 million of Nvidia.

These 5 Dividend Aristocrats® Have Raised Payouts for Decades
Investors worried about market turmoil may want to look at reliable dividend stocks, and these five stand out.

Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?
Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios...

Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?
The business has undergone major changes in recent years, and these might pay off over the medium term.

J&J funds Francis Medical to seek cancer indication for Vanquish device
Francis Medical’s water vapour ablation system secured FDA clearance for prostate tissue ablation in November 2025, and is now eyeing an oncology ex...

Johnson & Johnson Reports Favorable Data For Bipolar Study
Johnson & Johnson (NYSE:JNJ) reported topline results on Tuesday from Study 452, its second pivotal Phase 3 trial evaluating CAPLYTA (lumateperone...

Jim Cramer’s Top 5 Dividend Stocks for Safe, Consistent Returns
From 2000 through 2009, dividends earned S&P 500 investors an annualized 1.8%, according to Hartford Funds. Even with those payments, the index po...

Legend Biotech's Carvykti Positioned to Sustain Growth Into 2027, RBC Capital Markets Says
Legend Biotech's (LEGN) Carvykti therapy for multiple myeloma is positioned to sustain its growth in

Will HALO's Partner Royalties Drive Growth for the Rest of 2026?
Halozyme's royalty revenues surged 45.8% in the first nine months of 2026, prompting higher guidance.

ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?
AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges.

SGOV Yields 3.63%. Can Johnson & Johnson or Verizon Pay Retirees More?
One income stream resets every time the Fed moves, while two others depend on a board's vote and a balance sheet. Which payout holds up best over...

3 Legacy Health Care Dividend Stocks That Never Go Out of Style
Three health care giants have raised dividends for decades, yet each hides a catch that could shrink or stall a retiree's income. One faces lawsu...

Cyclicals Lead Sectors In Wednesday Trading As Defensives Trail
Five sectors are higher and six are lower in Wednesday's regular session, with cyclical sectors holding two of the top three positions. Techno...

Healthcare Just Hit a Record Lead Over Tech. 3 Things Could Shrink It
Healthcare stocks lead tech by 35.6 points over six months, the widest gap in 25 years, as investors cut AI exposure.

State Street Health Care SPDR (XLV) Sells Eli Lilly and J&J on Nov. 9
The fund sold $320.2 million of stock, cutting all 60 positions and adding nothing on Monday.

Can Gilead’s Cash Keep Growing?
For questions about this article or underlying research, email help@trefis.com.

Treasuries Now Offer 2.66% Above Inflation. Are Dividend Stocks in Trouble?
Real yields hit a level that crushed income stocks once before, and one dividend name is already repeating the old script. Which holdings sat out the ...

What an Unlikely Seat at the Table Taught a Former CEO About Leadership
Former EY Chairman and CEO Mark Weinberger says joining Saudi Aramco’s board was not an easy decision. Speaking with Poppy Harlow at the WSJ Leaders...

Is Johnson & Johnson (JNJ) Below Fair Value On Cash Flow?
Johnson & Johnson has delivered a powerful share price run in recent years, which puts a sharper spotlight on whether the current valuation lines ...

Bayer Wins FDA Approval for Sunharbo for Secondary Stroke Risk Reduction
Bayer gains FDA approval for Sunharbo, the first Factor XIa inhibitor approved worldwide, opening new growth opportunities in stroke prevention.

J&J's Oncology Sales Surge So Far in 2026: What Lies Ahead?
J&J's oncology sales surge 16.8% to $22 billion in the first nine months of 2026, fueled by blockbuster drugs and new launches.

The Kiplinger Dividend 15: Our Favorite Dividend-Paying Stocks
Rising interest rates create a risk for The Kiplinger Dividend 15, but our favorite dividend-paying stocks remain a worthy consideration for most port...

Is Current Price Of Stryker Stock A Strong Support?
For questions about this article or underlying research, email help@trefis.com.